Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.
One Health
; 12: 100214, 2021 Jun.
Article
in English
| MEDLINE | ID: covidwho-1009786
ABSTRACT
BACKGROUND:
Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID-19 and lung involvement.METHODS:
Observational study on a cohort of 418 patients, admitted to three county hospitals in Catalonia (Spain). Patients admitted consecutively were included and followed until discharge or up to 30â¯days of admission. A sub-cohort of patients treated with tocilizumab and a sub-cohort of control patients were identified, matched by a large number of risk factors and clinical variables. Sub-cohorts were also matched by the number of other treatments for COVID-19 that patients received. Increment in SAFI (inspired oxygen fraction / saturation) 48â¯h after the start of treatment, and time to discharge, were the primary outcomes. Mortality, which was a secondary outcome, was analyzed in the total cohort, by using logistic regression models, adjusted by confounders.RESULTS:
There were 96 patients treated with tocilizumab. Of them, 22 patients could be matched with an equivalent number of control patients. The increment in SAFI from baseline to 48â¯h of treatment, was not significantly different between groups (tocilizumab -0.04; control 0.09; pâ¯=â¯0.636). Also, no difference in time to discharge was found between the two sub-cohorts (logrank test pâ¯=â¯0.472). The logistic regression models, did not show an effect of tocilizumab on mortality (OR 0.99; pâ¯=â¯0.990).CONCLUSIONS:
We did not find a clinical benefit associated with the use tocilizumab, in terms of respiratory function at 48â¯h of treatment, or time to discharge.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
One Health
Year:
2021
Document Type:
Article
Affiliation country:
J.onehlt.2021.100214
Similar
MEDLINE
...
LILACS
LIS